The molecular interaction between adenosine A 2A and dopamine D 2 receptors (A 2A Rs and D 2 Rs, respectively) within an oligomeric complex has been postulated to play a pivotal role in the adenosine-dopamine interplay in the central nervous system, in both normal and pathological conditions (e.g. Parkinson's disease). While the effects of A 2A R challenge on D 2 R functioning have been largely studied, the reverse condition is still unexplored, a fact that might have impact in therapeutics. Here, we aimed to examine in a real-time mode the D 2 R-mediated allosteric modulation of A 2A R binding when an A 2A R/D 2 R oligomer is established. Thus, we synthesized fluorescent A 2A R agonists and evaluated, by means of a flow cytometry homogeneous no-wash assay and a real-time fluorescence resonance energy transfer (FRET)-based approach, the effects on A 2A R binding of distinct antiparkinsonian drugs in current clinical use (i.e. pramipexole, rotigotine and apomorphine). Our results provided evidence for the existence of a differential D 2 R-mediated negative allosteric modulation on A 2A R agonist binding that was oligomerformation dependent, and with apomorphine being the best antiparkinsonian drug attenuating A 2A R agonist binding. Overall, the here-developed methods were found valid to prospect the ability of drugs acting on D 2 Rs to modulate A 2A R binding, thus featuring as possible helpful tools for the preliminary selection of D 2 R-like candidate drugs in the management of Parkinson's disease.
Introduction
Parkinson's disease (PD) is a progressive systemic neurodegenerative disorder associated with, but not exclusively, the loss of pigmented dopaminergic neurons located at the substantia nigra pars compacta (Lang and Lozano, 1998) . Interestingly, the control of this circuitry both in normal and pathological conditions is not only mediated by dopamine receptors, but also by other G protein-coupled receptors (GPCRs), for instance adenosine receptors, which may functionally and molecularly interact with the dopaminergic system . Indeed, an interaction between adenosine A 2A and dopamine D 2 receptors (A 2A Rs and D 2 Rs, respectively) has been demonstrated in heterologous expression systems and there is accumulated evidence for the coexistence of reciprocal antagonistic interactions between A 2A Rs and D 2 Rs in the same neurons, the GABAergic enkephalinergic neurons (Ferre et al., 2008) . Thus, since drugs acting on A 2A Rs would modulate dopaminergic neurotransmission they have been proposed as therapeutic tools in PD, and in fact, A 2A R antagonists have been recently introduced in the symptomatic treatment of the former pathology (for review see (Xu et al., 2005 ,Morelli et al., 2009 ,Schwarzschild et al., 2006 ). Hence, it has been suggested that the modulation of a feasible A 2A R/D 2 R complex by means of simultaneous D 2 R activation and A 2A R inhibition would represent a valuable target for PD pharmacotherapy. Accordingly, in the present work we aimed to analyze the reciprocal A 2A R-D 2 R antagonistic interaction, concretely the possible D 2 R-mediated allosteric modulation of A 2A R agonist binding. Thus, by means of a real-time fluorescence resonance energy transfer (FRET)-and a flow cytometry-assays, we evaluated the effects of different antiparkinsonian drugs (i.e. pramipexole, rotigotine and apomorphine), in order to provide further information regarding D 2 R-based drugs before being selected for PD treatment.
Materials and Methods

Materials
The primary antibodies used were: rabbit anti-A 2A R polyclonal antibody , rabbit anti-D 2 R polyclonal antibody (Millipore, Temecula, CA, USA), and mouse anti-A 2A R monoclonal antibody (clone 7F6-G5-A2; Millipore). The secondary antibodies were: horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Pierce Biotechnology, Rockford, IL, USA) and Cy3-conjugated donkey anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). The ligands used were: adenosine, pramipexole, apomorphine from Sigma-Aldrich (St. Louis, MO, USA); CGS21680, ZM241,385, rotigotine from Tocris Bioscience (Ellisville, MI, USA). Adenosine deaminase was purchased from Roche Diagnostics (GmbH, Mannheim, Germany) and zardaverine from Calbiochem (San Diego, CA, USA).
Synthesis of the A 2A R fluorescent agonists
The APEC Alexa488 (MRS5206) and the APEC Alexa532 (MRS5424) are functional agonists at the adenosine A 2A R, in which the fluorescent dyes Alexa488 and 532, respectively, are covalently attached to the A 2A R agonist 2- [[2-[4-[2-(2-aminoethyl) -aminocarbonyl] ethyl]phenyl]ethylamino]-5′-N-ethyl-carboxamidoadenosine (APEC). MRS5424, and similarly MRS5206, were synthesized as previously described (Fernandez-Duenas et al., 2012) .
Plasmid constructs
To perform FRET experiments with the MRS5424 fluorescent agonist, a CFP-tagged A 2A R (A 2A R CFP ) and an AGT-tagged D 2 R (D 2 R AGT ) were cloned, as previously described (Fernandez-Duenas et al., 2012) .
Cell culture, transfection and membrane preparation
Human embryonic kidney (HEK)-293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 1 mM sodium pyruvate, 2 mM Lglutamine, 100 U/mL streptomycin, 100 mg/mL penicillin and 5% (v / v) fetal bovine serum at 37° C and in an atmosphere of 5% CO 2 . HEK-293 cells growing in 25 cm 2 flasks or sixwell plates containing 18 mm coverslips were used for western blot and fluorescence imaging, respectively, were transiently transfected with the cDNA encoding the specified proteins using TransFectin™ Lipid Reagent (Bio-Rad Laboratories, Hercules, CA, USA). Membrane suspensions from transfected HEK cells were obtained as described previously (Fernandez-Duenas et al., 2012) .
Gel electrophoresis, immunoblotting and immunocytochemistry
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) was performed using 7.5 % polyacrylamide gels. Proteins were transferred to PVDF membranes using a semi-dry transfer system, immunoblotted with the indicated antibodies and then bands detected using a chemiluminescent detection kit (Pierce). Immunocytochemistry experiments were performed as previously described (Ciruela et al., 2006) .
[ 3 H]-cAMP assay
The accumulation of cAMP was measured with a [ 3 H]-cAMP assay system (GE Healthcare, Piscataway, NJ, USA). In brief, transiently transfected HEK-293 cells were grown O/N in serum-free DMEM containing adenosine deaminase (0.5 U/mL), preincubated with 50 µM of the phosphodiesterase inhibitor zardaverine for 10 min and then stimulated with adenosine (10 µM) for 15 min at 37° C. Then, we performed the assay protocol, adding the labelled [ 3 H]-cAMP, as described in the manufacturer's manual. The radioactivity was determined in scintillation vials using a Packard 1600 TRI-CARB scintillation counter (PerkinElmer, Waltham, MA, USA).
Microscopic FRET measurements
Single-cell real-time FRET experiments with the MRS5424 ligand, in cells expressing the A 2A R CFP construct and the D 2 R AGT stained by means of the SNAP-Surface 647 ligand (New England BioLabs, Ipswich, MA, USA), were performed as previously described (Fernandez-Duenas et al., 2012) .
Flow cytometry analysis
Transiently transfected HEK-293 cells were detached with accutase (Sigma-Aldrich) and resuspended in Hank's balanced salt solution containing 1 g/l glucose (HBSS). Then, cells were incubated with the proper ligands in silicon-coated reaction vessels (3×10 5 cells/50 µl) during 60 minutes at room temperature and used directly for flow cytometric measurements. For each binding condition tested 10 4 cells were analyzed using a FACSCalibur™ flow cytometer (Becton Dickinson, Heidelberg, Germany) with excitation at 488 nm and emission at 510 nm. Samples were maintained in the dark during the analysis to avoid photobleaching. Fluorescence intensities were obtained in the FL-1 channel in log mode. Data were collected using Cell Quest Pro software (BD, Franklin Lakes, NJ) and analyzed by GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Statistics
The number of samples (n) in each experimental condition is indicated in figure legends. Statistical analysis was performed by one-way ANOVA followed by Dunnett`s multiple comparison post-hoc test. Statistical significance is indicated for each experiment.
Results and discussion
In the next years, the search for new drugs specifically targeting the A 2A R/D 2 R complex may represent a novel and therapeutically superior approach for the management of PD. In such way, drugs intended to overcome the tonic A 2A R-mediated inhibition of D 2 R signalling promise to be of great value. Accordingly, in the present work we aimed to study the D 2 Rmediated allosteric modulation of A 2A R agonist binding within the A 2A R/D 2 R oligomer framework. Hence, we developed a FRET-and a flow cytometry-based agonist binding assays devoted to study the adenosine-dopamine receptor-receptor interaction.
FRET determinations of D 2 R-mediated modulation of A 2A R binding
We recently described a single-cell real-time FRET-based A 2A R agonist binding procedure, in which it was possible to ascertain the negative allosteric modulatory effect of a D 2 R agonist (i.e. quinpirole) on A 2A R agonist binding (Fernandez-Duenas et al., 2012) . Accordingly, here we aimed to use the same experimental approach to analyze the effects of several clinically used antiparkinsonian drugs (i.e. pramipexole, rotigotine and apomorphine) on A 2A R agonist binding ( Figure 1A) . First, doubly A 2A R CFP and D 2 R AGT transfected cells were visualized at 480 nm (CFP) and 688 nm (SNAP; see methods). Noteworthy, the A 2A R CFP construct was, without losing its functionality, mostly targeted to the plasma membrane (see Supplementary Figure 1) , where it co-distributed with the D 2 R AGT (Fernandez-Duenas et al., 2012) . Then, we proceeded to analyze the effects of the antiparkinsonian agents on MRS5424 binding. Since it has been previously demonstrated that in real-time FRET determinations there is not receptor reserve and furthermore the measurements are done under continuous superfusion of the ligand (i.e. non-equilibrium conditions) (Ziegler et al., 2011) , high saturating concentrations of the antiparkinsonian D 2 R agonists (pramipexole: 120 µM, rotigotine: 1 µM and apomorphine: 6 µM) (Millan et al., 2002 ,Scheller et al., 2009 ) were used to displace the MRS5424 (2 µM) bound to A 2A Rs. Interestingly, while MRS5424 binding was unaffected by any of the D 2 R agonists in cells expressing only the A 2A R CFP (data not shown), upon D 2 R AGT co-expression and challenge a significant lower FRET signal was observed ( Figure 1B) . A close view of the real-time FRET profiles allowed us to discern that apomorphine (58±6%, p < 0.001) was the most efficacious negative allosteric modulator (NAM) of A 2A R agonist binding, when compared to rotigotine (29±5%, p < 0.001) or pramipexole (38±5%, p < 0.001) ( Figure 1C) . Overall, these results indicated that all D 2 R agonists tested were NAMs of A 2A R agonist binding, a phenomenon that would be dependent on A 2A R/D 2 R oligomerization. Indeed, we recently demonstrated that the formation of the A 2A R/D 2 R oligomer was mandatory for the observed receptor-receptor interaction (Fernandez-Duenas et al., 2012) .
Flow cytometric measurements of D 2 R-agonists effects on A 2A R binding
One of the main advantages of FRET-based approaches consists of providing high spatiotemporal resolution of the agonist-receptor interaction. On the contrary, this kind of tool does not permit the collection of a large number of events, therefore not suitable for high throughput screening of drugs. Accordingly, in order to validate our previous results by a different experimental approach and also to generate an easy, fast and reliable way for monitoring A 2A R-D 2 R interactions we aimed to develop a flow cytometry homogeneous nowash assay. First, a new selective A 2A R fluorescent agonist, a pure isomeric APEC Alexa488 named MRS5206, was synthesized according to our flow cytometer needs. First, it was tested to be bound selectively to the A 2A R by live-cell detection under a fluorescence microscope (see Supplementary Figure 2 ). And thereafter, we attempted to quantify the occurrence of MRS5206 binding to A 2A Rs by means of flow cytometry. To this end, A 2A R expressing cells were initially incubated with MRS5206 and then separated by flow cytometry with the aid of both forward and sideward scatter signals. Interestingly, while MRS5206 did not bind to mock transfected cells (data not shown), a concentrationdependent binding isotherm for A 2A R expressing cells was found when positive cells or events (Figure 2A, inset histogram) were plotted against MRS5206 concentration ( Figure  2A) . A close analysis of these results revealed that the maximal MRS5206 binding capacity identified ~33% of positive cells, and this was achieved at low nanomolar concentrations of MRS5206. This value may depend on the existing interrelation between cell surface receptor density and transfection efficiency achieved in our experiments. On the other hand, MRS5206 binding was completely blocked by ZM241,385 (1 µM) at any MRS5206 concentration tested, thus demonstrating the specificity of the fluorescent compound ( Figure  2A) . Also, we evaluated the affinity of MRS5206 by competitive ligand binding experiments. Thus, a fixed dose of MRS5206 (100 nM) was displaced with CGS21680, another A 2A R selective agonist, in a concentration-dependent manner ( Figure 2B ). The dissociation constant of CGS21680 (106±42 nM) was similar to that described in the literature by means of radioligand experiments (Ciruela et al., 2006) . Interestingly, these results were consistent with previous observations of fluorescent ligand binding for other GPCRs using flow cytometry under equilibrium conditions (Schneider et al., 2006) . Thus, we finally carried out flow cytometry binding experiments using the antiparkinsonian drugs. Importantly, while in cells transfected only with the A 2A R-containing plasmid the D 2 R agonists did not alter MRS5206 binding to A 2A Rs (data not shown), in A 2A R-D 2 R coexpressing cells all the antiparkinsonian agents tested produced a significant reduction of MRS5206 (100 nM) binding ( Figure 2C ), with apomorphine again achieving the largest binding inhibition (42±7%, p < 0.01) in comparison to rotigotine (22±3%, p < 0.01) and pramipexole (29±7%, p < 0.01) ( Figure 2C ).
Conclusion
The two different experimental approaches presented here permitted us to evaluate the degree of D 2 R-mediated allosteric modulation of A 2A R agonist binding within the A 2A R/ D 2 R oligomer framework. Hence, it could be concluded that both our FRET-and flow cytometry-based agonist binding assays would be valuable for determining the D 2 R agonist NAM activity of different antiparkinsonian agents over A 2A R functioning. Needless to say, the relevance of this information for the design of effective D 2 R-based antiparkinsonian therapies is intrinsically limited, since the experiments were performed in a heterologous system. Thus, it is important to keep in mind that any new emerging D 2 R-based drug with A 2A R NAM activity should be first tested in PD animal models before attempting some clinical extrapolation. And on the other hand, it would also be important to correlate the degree of the discovered properties of apomorphine, rotigotine, and pramipexole with their effectiveness as antiparkinsonian drugs. Overall, the present methods are mainly circumscribed to the mechanistic elucidation of the receptor-receptor interaction occurring between A 2A Rs and D 2 Rs, but they may also be viewed as possible complementary tools on the development of D 2 R-like drugs targeted to the management of Parkinson's disease.
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